Recent Finacing
Recent Raise
89Bio is a clinical-stage biopharmaceutical company developing pegozafermin (a glycopegylated FGF21 analogue) and other biologic/small-molecule therapies for liver and metabolic diseases, conducting Phase II/III trials.
Focus Areas
Recent Investors
Total Raised
Funding rounds
Investors
See the team members at 89bio.
